

10/004,708

PATENT

3762

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: KRISHNAN *et al.* Examiner: Unassigned
Serial No.: 10/004,708 Group Art Unit: 3762
Filed: December 4, 2001 Docket No.: GUID.031US01
Title: APPARATUS AND METHOD FOR STABILIZING AN IMPLANTABLE LEAD

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence and the papers, as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on February 11, 2003.

By: *Rennae Johnson*
Rennae Johnson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED**FEB 21 2003**

TECHNOLOGY CENTER R3700

Dear Sir:

The above-referenced application is related to the following pending application:

Serial Number 10/353,793 (GUID.035US01) filed on January 29, 2003,
for applicant Westlund *et al.*

Applicant respectfully submits the items of information on the enclosed Form
1449 for the attention of the Examiner in the above-identified application.

Applicant would like to bring to the attention of the Examiner the following
references, copies of which were not available:

- Bellon JM, Garcia-Carranza A, Jurado F, Garcia-Honduvilla N, Carrera-San Martin A, Bujan J, "Peritoneal regeneration after implant of a composite prosthesis in abdominal wall". World J Surg. 2001 Feb;25(2):147-52. PMID: 11338014.
- Lumsden AB, MacDonald MJ, Kikeri D, Cotsonis GA, Harker LA, Martin LG, Cost efficacy of duplex surveillance and prophylactic angioplasty arteriovenous ePTFE grafts". Ann Vasc Surg. 1998 Mar;12(2):138-42. PMID:9514231 [PubMed-indexed for MEDLINE].

- Salzman DL, Yee DC, Roach DJ, Berman SS, Williams SK. *Effects of balloon dilatation on ePTFE structural characteristics*. J Biomed Mater Res. 1997 Sep 15;36(4):498-507. PMID:9294765 [PubMed-indexed for MEDLINE]
- Walluscheck KP, Steinhoff G, Kelm S, Haverich A. *Improved endothelial cell attachment on ePTFE vascular grafts pretreated with synthetic RGD-containing peptides*. Eur J Vasc Endovasc Surg. 1996 Oct;12(3):321-30. PMID: 8896475 [PubMed-indexed for MEDLINE]
- Gillion JF, Elhadad A, Balique JG, Fourtanier G. [Two-year results of celioscopic hernioplasties using an intraperitoneal ePTFE patch. A prospective multicenter study of 184 cases. Group CHIC (Cure des hernies inguinocrurales sous coelioscopie)]. Ann Chir. 1996;50(9):799-802. French. PMID: 9124788 [PubMed-indexed for MEDLINE].
- Cho JS, Ouriel K, DeWeese JA, Green RM, Chen GY, Stoughton, J. Thrombus formation on polytetrafluoroethylene surfaces: the importance of von Willebrand factor. Cardiovasc Surg. 1995 Dec;3(6):645-51. PMID:8745188[PubMed-indexed for MEDLINE].
- Carr HM, Smyth JV, Rooney OB, Dodd PD, Sharma H, Walker MG. Limitations of in-vitro labeling of endothelial cells with indium 111 oxine. Cell Transplant. 1995 May-Jun;4(3):291-6. PMID: 7640868 [PubMed-indexed for MEDLINE].
- Waldrop TC, Semba SE. Closure of oroantral communication using guided tissue regeneration and an absorbable gelatin membrane. J Periodontol. 1993 Nov;64(11):1061-6. PMID: 8295091 [PubMed-indexed for MEDLINE].
- Guillemin MR, Mellonig JT, Brunsvold MA, Steffensen B. Healing in periodontal defects treated by decalcified freeze-dried allografts in combination with ePTFE membranes. Assessment by computerized densitometric analysis. J Clin Periodontol. 1993 Aug;20(7):520-7. PMID: 8354728 [PubMed-indexed for MEDLINE].
- Geiger G, Hoevels J, Storz L, Bayer HP. Vascular grafts in below-knee femoropopliteal bypass. A comparative study. J Cardiovasc Surg (Torino). 1984 Nov-Dec;25(6):523-9. PMID: 6239870 [PubMed-indexed for MEDLINE].

This statement should be considered because it is submitted either within three months of the filing date or before the first Office Action of the above-identified application. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

A copy of each document or other information listed on the enclosed Form 1449 is enclosed in accordance with 37 C.F.R. §1.98(a)(2) and/or a copy of each document is not provided because it was previously cited by or submitted to the U.S. Patent and Trademark Office in a parent application in accordance with 37 C.F.R. §1.98(d).

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§102 and 103. In addition, Applicant(s) do(es) not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended, and reserve the right to establish otherwise under 37 C.F.R. §1.131 or others.

Consideration of the items listed is respectfully requested. According to M.P.E.P. §609, Applicant(s) request(s) that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Authorization is hereby given to charge any additional fees or credit any overpayments that may be deemed necessary to Deposit Account Number 50-0996 (GUID.031US01).

Please direct all correspondence to:

CRAWFORD MAUNU PLLC
1270 Northland Drive, Suite 390
St. Paul, Minnesota 55120
(651) 686-6633

February 11, 2003

Respectfully submitted,

By: 
Name: Mark A. Hollingsworth
Reg. No.: 38,491

A circular black ink stamp from the OIPE Patent & Trademark Office. The text "OIPE" is at the top, "FEB 19 2003" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom. The date is stamped in a slightly larger font than the office name.

RECEIVED

~~FEB 21 2003~~

TECHNOLOGY CENTER R3700

*Substitute Disclosure Statement Form (PTO-1449)